Fresh blood in hematology
18 November 2020
Bottom line:
The hematology market has experienced substantial growth and demonstrated the crucial value of innovation, which also contributed to its highly competitive dynamic. Within these lines we believe that a profound understanding of the underlying science of each program and market application is crucial for picking the technologies and companies with a real potential to differentiate.
As outlined in the article, we are focusing on the antibody space, notably on the bi-specifics, as well as on the cell therapy space, offering sizeable market opportunities for novel technologies. We have been building exposure to these segments in our portfolios over the past months and are looking to increase it depending on the data that will be provided at the upcoming ASH conference.
This article is available to logged users.
Sign in or request a login.
Disclaimer
This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.
As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.
The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.
Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.
It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.
Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.
Back to research
